PetVivo (PETV) 10-Q 10 Feb 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Dec. 31, 2021	Feb. 08, 2022
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--03-31
Entity File Number	000-55167
Entity Registrant Name	PetVivo Holdings Inc.
Entity Central Index Key	0001512922
Entity Tax Identification Number	99-0363559
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5251 Edina Industrial Blvd.
Entity Address, City or Town	Edina
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55439
City Area Code	(952)
Local Phone Number	405-6216
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,775,228
Common Stock Par Value 0.001 [Member]
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	PETV
Security Exchange Name	NASDAQ
Warrants to Purchase Common Stock [Member]
Title of 12(b) Security	Warrants to purchase Common Stock
Trading Symbol	PETVW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Current Assets
Cash and cash equivalents	$ 7,553,738	$ 23,578
Accounts receivable	3,186
Inventory, net	104,965
Prepaid expenses and other assets	373,505	123,575
Total Current Assets	8,035,394	147,153
Property and Equipment, net	269,226	214,038
Other Assets:
Deferred offering costs		280,163
Operating lease right-of-use asset	137,921	157,760
Patents and trademarks, net	40,738	27,932
Security deposits	12,830	8,201
Total Other Assets	191,489	474,056
Total Assets	8,496,109	835,247
Current Liabilities
Accounts payable	263,267	408,873
Accrued expenses	805,937	554,012
Convertible notes and accrued interest		235,671
Accrued expenses – related parties		36,808
Operating lease liability – current portion	27,011	26,582
PPP Loan and accrued interest	3,769	39,020
Notes payable and accrued interest - directors		20,000
Notes payable and accrued interest – related party		44,554
Note payable and accrued interest (current portion)	6,456	39,528
Total Current Liabilities	1,106,440	1,405,048
Other Liabilities
Note payable and accrued interest (net of current portion)	28,837
Operating lease liability (net of current portion)	110,910	131,178
Share-settled debt obligation – related party, net of debt discount		196,000
Total Other Liabilities	139,747	327,178
Total Liabilities	1,246,187	1,732,226
Commitments and Contingencies (see Note 13)
Stockholders’ Equity (Deficit):
Preferred stock, par value $0.001, 20,000,000 shares authorized, issued 0 and 0 shares outstanding at December 31, 2021 and March 31, 2021
Common stock, par value $0.001, 250,000,000 shares authorized, issued 9,757,728 and 6,799,113 shares outstanding at December 31, 2021 and March 31, 2021, respectively	9,758	6,799
Additional Paid-In Capital	68,589,822	57,207,648
Accumulated Deficit	(61,349,658)	(58,111,426)
Total Stockholders’ Equity (Deficit)	7,249,922	(896,979)
Total Liabilities and Stockholders’ Equity (Deficit)	$ 8,496,109	$ 835,247

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Mar. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	9,757,728	6,799,113
Common stock, shares outstanding	9,757,728	6,799,113

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenues	$ 51,004	$ 507	$ 60,126	$ 7,303
Cost of Sales	98,997		104,048	350
Gross Profit (Loss)	(47,993)	507	(43,922)	6,953
Operating Expenses:
Sales and Marketing	404,462	24,484	689,960	106,745
Research and Development	34,326	30,265	287,643	30,265
General and Administrative	1,170,870	331,148	2,258,001	1,515,968
Total Operating Expenses	1,609,658	385,897	3,235,604	1,652,978
Operating Loss	(1,657,651)	(385,390)	(3,279,526)	(1,646,025)
Other Income (Expense)
Gain on Sale of Asset				482
Gain on Debt Restructuring				516
Gain on Debt Extinguishment		366,903		366,903
Forgiveness of PPP loan and accrued interest			31,680
Derivative Expense		(970,600)		(1,702,100)
Interest Income (Expense)	15,522	(48,666)	9,614	(219,539)
Total Other Income (Expense)	15,522	(652,363)	41,294	(1,553,738)
Net Loss before taxes	(1,642,129)	(1,037,753)	(3,238,232)	(3,199,763)
Income Tax Provision
Net Loss	$ (1,642,129)	$ (1,037,753)	$ (3,238,232)	$ (3,199,763)
Net Loss Per Share:
Basic and Diluted	$ (0.17)	$ (0.16)	$ (0.38)	$ (0.53)
Weighted Average Common Shares Outstanding:
Basic and Diluted	9,756,945	6,442,549	8,426,135	6,006,382

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes In Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Common Stock To Be Issued [Member]	Total
Beginning balance, value at Mar. 31, 2020	$ 5,728	$ 53,494,747	$ (54,588,645)	$ 52,000	$ (1,036,170)
Beginning balance, shares at Mar. 31, 2020	5,727,965
Common stock and warrants sold	$ 20	51,980		(54,000)
Common stock and warrants sold, shares	20,000
Warrants issued with convertible debt		91,500			91,500
Stock-based Compensation	$ 30	183,214			183,244
Stock-based Compensation, shares	30,000
Net loss			(814,008)		(814,008)
Ending balance, value at Jun. 30, 2020	$ 5,788	53,821,442	(55,402,653)		(1,575,433)
Ending balance, shares at Jun. 30, 2020	5,777,965
Beginning balance, value at Mar. 31, 2020	$ 5,728	53,494,747	(54,588,645)	52,000	(1,036,170)
Beginning balance, shares at Mar. 31, 2020	5,727,965
Net loss					(3,199,763)
Ending balance, value at Dec. 31, 2020	$ 6,719	57,119,733	(57,788,408)		(661,956)
Ending balance, shares at Dec. 31, 2020	6,718,979
Beginning balance, value at Jun. 30, 2020	$ 5,788	53,821,442	(55,402,653)		(1,575,433)
Beginning balance, shares at Jun. 30, 2020	5,777,965
Common stock sold	$ 226	316,274			316,500
Common stock sold, shares	226,072
Stock issued for debt conversion	$ 25	25,357			25,382
Stock issued for debt conversion, shares	25,002
Cashless warrant exercises	$ 15	(15)
Cashless warrant exercises, shares	15,257
Stock-based Compensation	$ 175	653,688			653,863
Stock-based Compensation, shares	174,752
Net loss			(1,348,002)		(1,348,002)
Ending balance, value at Sep. 30, 2020	$ 6,219	54,816,746	(56,750,655)		(1,927,690)
Ending balance, shares at Sep. 30, 2020	6,219,048
Cash paid to exercise warrants	$ 202	449,791			449,993
Cash paid to exercise warrants, shares	202,499
Stock issued for debt conversion	$ 264	1,728,741			1,729,005
Stock issued for debt conversion, shares	263,568
Cashless warrant exercises	$ 33	(33)
Cashless warrant exercises, shares	33,140
1-for-4 reverse split rounding	$ 1	(1)
1-for-4 reverse split rounding, shares	724
Stock issued for services		72,000			72,000
Stock issued for services, shares
Stock-based Compensation		52,490			52,490
Stock-based Compensation, shares
Net loss			(1,037,753)		(1,037,753)
Ending balance, value at Dec. 31, 2020	$ 6,719	57,119,733	(57,788,408)		(661,956)
Ending balance, shares at Dec. 31, 2020	6,718,979
Beginning balance, value at Mar. 31, 2021	$ 6,799	57,207,648	(58,111,426)		(896,979)
Beginning balance, shares at Mar. 31, 2021	6,799,113
Common stock sold	$ 50	343,048			343,098
Common stock sold, shares	49,014
Cash paid to exercise warrants	$ 4	39,996			40,000
Cash paid to exercise warrants, shares	4,500
Stock issued for debt conversion	$ 80	232,578			232,658
Stock issued for debt conversion, shares	80,522
Cashless warrant exercises	$ 160	(160)
Cashless warrant exercises, shares	160,006
Stock-based Compensation		55,674			55,674
Stock-based Compensation, shares
Net loss			(490,629)		(490,629)
Ending balance, value at Jun. 30, 2021	$ 7,093	57,878,784	(58,602,055)		(716,178)
Ending balance, shares at Jun. 30, 2021	7,093,155
Beginning balance, value at Mar. 31, 2021	$ 6,799	57,207,648	(58,111,426)		(896,979)
Beginning balance, shares at Mar. 31, 2021	6,799,113
Net loss					(3,238,232)
Ending balance, value at Dec. 31, 2021	$ 9,758	68,589,822	(61,349,658)		7,249,922
Ending balance, shares at Dec. 31, 2021	9,757,728
Beginning balance, value at Jun. 30, 2021	$ 7,093	57,878,784	(58,602,055)		(716,178)
Beginning balance, shares at Jun. 30, 2021	7,093,155
Common stock sold	$ 2,511	4,966,020			4,968,531
Common stock sold, shares	2,511,000
Warrants sold		4,889,252			4,889,252
Cash paid to exercise warrants	$ 1	2,030			2,031
Cash paid to exercise warrants, shares	1,594
Cashless warrant exercises	$ 40	(40)
Cashless warrant exercises, shares	40,038
Stock issued for investor relations services	$ 42	209,958			210,000
Stock issued for investor relations services, shares	42,000
Stock-based Compensation		104,092			104,092
Stock-based Compensation, shares
Stock and warrants granted for debt conversion	$ 44	195,956			196,000
Stock and warrants granted for debt conversion, shares	43,556
Net loss			(1,105,474)		(1,105,474)
Ending balance, value at Sep. 30, 2021	$ 9,731	68,246,052	(59,707,529)		8,548,254
Ending balance, shares at Sep. 30, 2021	9,731,343
Stock issued for services	$ 27	71,053			71,080
Stock issued for services, shares	26,085
Vesting of restricted stock units
Vesting of restricted stock unit shares	300
Stock-based Compensation		272,717			272,717
Stock-based Compensation, shares
Net loss			(1,642,129)		(1,642,129)
Ending balance, value at Dec. 31, 2021	$ 9,758	$ 68,589,822	$ (61,349,658)		$ 7,249,922
Ending balance, shares at Dec. 31, 2021	9,757,728

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss For The Period	$ (3,238,232)	$ (3,199,763)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Derivative expense		1,702,100
Stock-based compensation	432,483	889,597
Stock issued for services	71,080	72,000
Depreciation and amortization	43,168	73,062
Amortization of debt discount		173,174
Forgiveness of PPP loan and accrued interest	(31,680)
Intangible impairment		23,930
Gain on debt restructuring		(516)
Gain on sale of asset		(482)
Changes in Operating Assets and Liabilities
Increase in prepaid expenses and other assets	(44,659)	(120,408)
Increase in accounts receivable	(3,186)	(1,250)
Increase in inventories	(104,965)	(9,971)
Interest accrued on convertible notes payable	(3,013)	37,150
Interest accrued on notes payable - related party	4,013	7,011
Interest accrued on notes payable		2,823
Increase (decrease) in accounts payable and accrued expense	106,319	(10,924)
Increase (decrease) in accrued expenses - related party	(36,808)	(47,475)
Net Cash Used In Operating Activities	(2,805,480)	(776,845)
CASH FLOWS FROM INVESTING ACTIVITIES
Sale of equipment		482
Purchase of equipment	(91,908)	(118,424)
Disbursements for patents and trademarks	(19,154)	(39,817)
Net Cash Used in Investing Activities	(111,062)	(157,759)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from stock and warrants sold	10,200,881	316,500
Proceeds from exercise of warrants	42,031	449,993
Decrease in deferred offering costs	280,163
Equity sale proceeds receivable		52,000
Proceeds from PPP loan		38,665
Proceeds from notes payable		27,500
Proceeds from convertible notes		322,500
Repayments of convertible notes		(28,077)
Repayments of notes payable	(4,235)	(4,190)
Repayments of PPP loan	(3,571)
Repayments of notes payable - related party	(48,267)	(19,900)
Repayments of notes payable - directors	(20,300)
Net Cash Provided by Financing Activities	10,446,702	1,154,991
Net Increase in Cash and Cash Equivalents	7,530,160	220,837
Cash and Cash Equivalents at Beginning of Period	23,578	10,582
Cash and Cash Equivalents at End of Period	7,553,738	230,969
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest	9,071	45,850
SUPPLEMENTAL DISCLOSURE ON NON-CASH FINANCING AND INVESTING ACTIVITIES
Derivative treated as debt discount		352,941
Stock granted for debt conversion	232,658	1,729,005
Stock granted for share-settled debt obligation conversion	196,000
Stock granted for investor relations services	210,000
Note payable – related party granted for release of claim to accrued salary		196,000
Note payable – related party converted into common stock		$ 25,382

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	9 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Organization and Description The Company is in the business of commercializing its proprietary medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in Minneapolis, Minnesota. (B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. In October 2020, the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was effectuated on December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 250,000,000 (C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations, Gel-Del Technologies, Inc. and PetVivo, Inc. All intercompany accounts have been eliminated upon consolidation. (D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangibles, estimate of fair value of share-based payments and derivative instruments and recorded debt discount and valuation of deferred tax assets. (E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had no (F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. As of December 31, 2021, the Company did have cash balances in excess of the federally insured limits. At March 31, 2021, the Company did not have any cash balances in excess of the federally insured limits. (H) Property & Equipment Property and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after considering their respective estimated residual values) over the assets estimated useful life of ( 3 5 7 (I) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of a useful life of 60 months (J) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 3,754,484 1.20 6.67 4.95 The Company has 1,124,803 1.20 15.53 1.99 The Company uses the guidance in Accounting Standards Codification 260 (“ASC 260”) to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be antidilutive. At December 31, 2020, the Company had $ 280,000 0 June 30, 2021 280,000 0 96,924 2.89 196,000 (K) Revenue Recognition The Company derives revenue from the sale of pet care products to its veterinarian customers in the Unites States. For performance obligations related to the sale of our pet care products, control transfers to the customer at a point in time. Revenue is recognized upon shipment, which is when control of these products is transferred to our customers and in an amount that reflects the consideration the Company expects to receive for these products. Shipping costs charged to customers are not reported within revenue. The Company does not have any significant financing components as payment is received at or shortly after the point of sale. (L) Accounts Receivable Accounts receivable are recorded at management’s assessment of the expected consideration to be received, based on a detailed review of historical pricing adjustments and collections. Management relies on the results of the assessment, which includes payment history of the applicable customer as a primary source of information in estimating the collectability of our accounts receivable. We update our assessment on a quarterly basis, which to date has not resulted in any material adjustments to the valuation of our accounts receivable. We believe the assessment provides reasonable estimates of our accounts receivable valuation, and therefore believe that substantially all accounts receivable are fully collectible. (M) Research and Development The Company expenses research and development costs as incurred. (N) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, accrued expenses – related parties, notes payable and accrued interest, and notes payable and accrued interest - related party, notes payable – directors and others. The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2021 and March 31, 2021, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company had no (O) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised. (P) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. As required by ASC Topic 450, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses. (Q) Inventory Inventories are recorded in accordance with ASC 330, Inventory, and are stated at the lower of cost or net realizable value. We account for inventories using the first in first out (FIFO) methodology. (R) Recent Accounting Pronouncements The Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) - Accounting for Convertible Instruments and Contracts on an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exceptions. The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of the standard on the consolidated financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). The new ASU addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact this new guidance will have on its financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. (S) Reclassifications A certain account in the prior year financial statements has been reclassified for comparative purposes to conform with the presentation in the current year financial statements. Accrued expenses is reported separately from accounts payable in the balance sheet since the amounts are material. There was no effect on the change in net assets resulting from the reclassifications.

INVENTORY

INVENTORY	9 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
INVENTORY	NOTE 2 – INVENTORY As of December 31, 2021 and March 31, 2021, the Company had inventory of $ 104,965 47,068 47,068 The inventory components are as follows: SCHEDULE OF INVENTORY December 31, 2021 March 31, 2021 Finished Goods $ 8,520 $ 36,973 Work in Process 31,424 - Raw Materials 65,021 8,773 Manufacturing Supplies - 1,322 Inventory, Gross 104,965 47,068 Reserve for Obsolete Inventory - (47,068 ) Total Net $ 104,965 $ - At December 31, 2021, both the inventory cost of $ 47,068 The Company recognized a benefit to cost of sales of $ 3,289

PREPAID EXPENSES AND DEFERRED O

PREPAID EXPENSES AND DEFERRED OFFERING COSTS	9 Months Ended
	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND DEFERRED OFFERING COSTS	NOTE 3 – PREPAID EXPENSES AND DEFERRED OFFERING COSTS As of December 31, 2021, the Company had $ 373,505 245,000 82,000 36,000 As of March 31, 2021, the Company had $ 123,575 78,000 9,000 9,000 280,163

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 – PROPERTY AND EQUIPMENT The components of property and equipment were as follows: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, 2021 March 31, 2021 Leasehold improvements $ 214,354 $ 198,015 Production equipment 165,753 128,849 R&D equipment 25,184 25,184 Computer equipment and furniture 48,895 10,130 Total, at cost 454,086 362,178 Accumulated depreciation (184,960 ) (148,140 ) Total Net $ 269,226 $ 214,038 During the three months ended December 31, 2021 and 2020, depreciation expense was $ 13,123 10,768 36,820 24,731

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 5 – INTANGIBLE ASSETS The components of intangible assets, all of which are finite-lived, were as follows: SCHEDULE OF INTANGIBLE ASSETS December 31, 2021 March 31, 2021 Patents $ 3,860,057 $ 3,840,903 Trademarks 26,142 26,142 Total at cost 3,886,199 3,867,045 Accumulated Amortization (3,845,461 ) (3,839,113 ) Total net $ 40,738 $ 27,932 During the three-month periods ended December 31, 2021 and 2020, amortization expense was $ 2,286 1,629 6,348 8,353

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Dec. 31, 2021
Accrued Expenses
ACCRUED EXPENSES	NOTE 6 – ACCRUED EXPENSES The components of accrued expenses were as follows: SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES December 31, 2021 March 31, 2021 Accrued payroll and related taxes $ 473,699 $ 221,774 Accrued lease termination expense 332,238 332,238 Total $ 805,937 $ 554,012 Pursuant to a lease wherein our subsidiary, Gel-Del Technologies, Inc., was the lessee until and through the lease’s termination in fiscal year 2017-2018, the Company had recorded as of those fiscal years approximately $ 332,000

RELATED PARTY NOTES PAYABLE

RELATED PARTY NOTES PAYABLE	9 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY NOTES PAYABLE	NOTE 7 - RELATED PARTY NOTES PAYABLE At December 31, 2021 and March 31, 2021, the Company is obligated for a related party note payable and accrued interest in the total amount of $ 0 44,554 April 30, 2020 3,100 24 3,500,000 The Company entered into notes payable with four directors in March 2021 which accrue interest at a rate of 6 0 20,000

NOTES PAYABLE AND CONVERTIBLE N

NOTES PAYABLE AND CONVERTIBLE NOTES	9 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE AND CONVERTIBLE NOTES	NOTE 8 – NOTES PAYABLE AND CONVERTIBLE NOTES In January 2020, the Company entered into a lease amendment for our corporate office facility whereby the lease term was extended through November of 2026 in exchange for a loan of $ 42,500 6 35,100 39,528 6,456 28,837 On May 1, 2020, the Company received $ 38,665 39,020 1 May 1, 2022 31,680 3,769 738 At March 31, 2021, the Company is obligated for several convertible notes payable in the total amount of $ 235,671 230,000 5,671 10 2,658 80,522 2.89 At September 30, 2020, the Company is obligated for one convertible note payable held by RedDiamond Partners, LLC (“RDCN”); the Company entered into the RDCN on June 15, 2020, whereby the note is convertible on or after January 15, 2021 and before maturity on March 15, 2021 at a rate of $ .28 352,941 52,941 15 365,808 352,941 12,867 557,143 91,500 0 352,941 91,500 2,500 2,500 52,941 52,941 206,000 215,686 0 137,255 30,000 75,000 31,500 61,500 52,399 173,174 368,995 352,941 16,054 263,568 1.40 6.56 1,908,100 368,995 181,187 1,729,005 366,903 0 0

SHARE-SETTLED DEBT OBLIGATION _

SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY	9 Months Ended
	Dec. 31, 2021
Share-settled Debt Obligation Related Party
SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY	NOTE 9 – SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY Effective September 1, 2020, the Company entered into two debt settlement agreements with David B. Masters, a director of the Company, pursuant to an Amendment to Promissory Note and a Promissory Note. The Amendment to Promissory Note extends, for up to an additional two years and under the same terms as originally entered into, the original promissory notes which were issued by Gel-Del Technologies, Inc., a wholly owned subsidiary of the Company, to Dr. Masters. Because this Amendment to Promissory Note simply extended the term over which the Company is required to pay back the outstanding balance this change has been treated as a debt modification. The outstanding principal of $ 59,642 6,058 65,700 8 20 The Amendment to Promissory Note requires monthly payments of $ 3,100 June 30, 2022 The Promissory Note was entered into with an effective date of September 1, 2020 in a principal amount of $ 195,000 David Masters’ release of any claim to the $195,000 in past accrued salary he was owed, it accrues interest at a rate of 3 August 31, 2022 4,000 195,000 A Settlement and General Release (“ Settlement Agreement On October 15, 2020, the Company entered into a note conversion agreement with David Masters whereby the Company and Dr. Masters both agreed to convert his note payable in the then outstanding balance of $ 193,158 192,500 658 196,000 192,500 3,500 658 3,500 196,000 43,556 43,556 43,556 At December 31, 2021 and March 31, 2021, the Company was obligated for principal and accrued interest in the amounts of $- 0 196,000 0 44,554

DERIVATIVE LIABILITY AND EXPENS

DERIVATIVE LIABILITY AND EXPENSE	9 Months Ended
	Dec. 31, 2021
Derivative Liability And Expense
DERIVATIVE LIABILITY AND EXPENSE	NOTE 10 – DERIVATIVE LIABILITY AND EXPENSE The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operation as other income (expense). Upon conversion or exercise of a derivative instruments, the instrument is marked to fair value at the conversion date then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. The Company used the following assumptions for determining the fair value of the conversion feature in the RDCN referenced in Note 8 to these financial statements, under the binomial pricing model with Monte Carlo simulations at June 15, 2020, September 30, 2020 and October 26, 2020, the issuance, balance sheet, and conversion dates, respectively: SCHEDULE OF DERIVATIVE LIABILITY ASSUMPTIONS June 15, 2020 September 30, 2020 October 26,2020 Stock price on valuation date $ .42 $ .80 $ 6.56 Conversion price $ .28 $ .28 $ 1.12 Days to maturity 273 166 140 Weighted-average volatility* 367 % 327 197 % Risk-free rate .18 % .12 .11 % The initial valuation of $ 526,800 206,000 0 320,800 526,800 937,500 389,300 263,568 1.40 366,903 no

ACCRUED EXPENSES _ RELATED PART

ACCRUED EXPENSES – RELATED PARTY	9 Months Ended
	Dec. 31, 2021
Accrued Expenses Related Party
ACCRUED EXPENSES – RELATED PARTY	NOTE 11– ACCRUED EXPENSES – RELATED PARTY At March 31, 2021, the Company was obligated to pay $ 36,808 28,965 7,843 In August 2021, the total amount due to the related party was paid from the proceeds of its Public Offering and there is no

RETIREMENT PLAN

RETIREMENT PLAN	9 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
RETIREMENT PLAN	NOTE 12– RETIREMENT PLAN In February 2021, the Company established a 401(k)-retirement plan for its employees in which eligible employees can contribute a percentage of their compensation. The Company may also make discretionary contributions. The Company made contributions to the plan for the three and nine months ended December 31, 2021 of $ 2,350

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 13 – COMMITMENTS AND CONTINGENCIES The Company entered into an eighty-four-month lease for 3,577 2 In January 2020, the Company entered into a lease amendment whereby agreed to extend the lease term through November of 2026 42,500 7,500 2,205 Rent expense for the three-month periods ended December 31, 2021 and December 31, 2020 were $ 16,549 13,343 50,952 40,479 The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of December 31, 2021: SCHEDULE OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY 2022 $ 6,745 2023 27,167 2024 27,710 2025 28,265 2026 28,830 2027 19,475 Total 138,192 Less: amount representing interest (271 ) Total $ 137,921 In compliance with ASC 842, the Company recognized, based on the extended lease term to November 2026 and a treasury rate of 0.12 189,600 6 0.12 SCHEDULE OF BASE RENT LEASE PAYMENTS Present value of future base rent lease payments $ 137,921 Present value of future base rent lease payments – net $ 137,921 As of December 31, 2021, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES Operating lease right-of-use asset $ 137,921 Total operating lease assets 137,921 Operating lease current liability 27,011 Operating lease other liability 110,910 Total operating lease liabilities $ 137,921 The Company has employment agreements with its executive officers. As of December 31, 2021, these agreements contain severance benefits ranging from one month to six months if terminated without cause. As of March 31, 2021, the employment agreements to executive officers did not contain severance benefits if terminated without cause. The Company has received correspondence from an attorney representing Dr. David Masters, our former Chief Technology Officer and current director, alleging that the Company, among other items, breached its settlement and consulting agreement with him and owes him additional monies pursuant to these agreements. His attorney also alleges that the Company promised to enter into a new employment agreement with him and failed to fulfill that promise. The Company believes that Dr. Master’s claims are without merit and has retained legal counsel. The Company does not believe that this matter will have a material impact on its financial position or results of operations.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 14 - GOING CONCERN The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The financial statements have been prepared assuming that we will continue as a going concern, which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business. In August 2021, we raised net proceeds of approximately $ 9,781,000 2,500,000 4.50 6,928,954 The Company expects to incur losses in the future as its commercially launches its first product. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months after the date of issuance of these financial statements. Management intends to raise additional funds by selling securities in public or private offerings. Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern. While the Company believes in its viability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and raise additional funds. COVID-19 has had an impact on the global economy, which directly or indirectly may have an impact on our ability to continue as a going concern.

COMMON STOCK AND WARRANTS

COMMON STOCK AND WARRANTS	9 Months Ended
	Dec. 31, 2021
Common Stock And Warrants
COMMON STOCK AND WARRANTS	NOTE 15 – COMMON STOCK AND WARRANTS Equity Incentive Plan On July 10, 2020, our Board of Directors unanimously approved the PetVivo Holdings, Inc “2020 Equity Incentive Plan” (the “2020 Plan”), subject to approval by our stockholders at a Meeting of Stockholders held on September 22, 2020, when it was approved by our stockholders and became effective. The number of shares of our common stock authorized under the 2020 Plan is 1,000,000 July 10, 2030 450,435 Employees, consultants and advisors of the Company (or any subsidiary), and non-employee directors of the Company will be eligible to receive awards under the 2020 Plan. In the case of consultants and advisors, however, their services cannot be in connection with the offer and sale of securities in a capital-raising transaction nor directly or indirectly promote or maintain a market for PetVivo securities. The 2020 Plan is administered by the Compensation Committee of our Board of Directors (the “Committee”), which has full power and authority to determine when and to whom awards will be granted, and the type, amount, form of payment, any deferral payment, and other terms and conditions of each award. Subject to provisions of the 2020 Plan, the Committee may amend or waive the terms and conditions, or accelerate the exercisability, of an outstanding award. The Committee has the authority to interpret and establish rules and regulations for the administration of the 2020 Plan. In addition, the Board of Directors may also exercise the powers of the Committee. The aggregate number of shares of PetVivo common stock available and reserved to be issued under the 2020 Plan is 1,000,000 ● the maximum aggregate number of shares of Common Stock granted as an Award to any Non-Employee Director in any one Plan Year will be 25,000 Awards can be granted for no cash consideration or for any cash and other consideration as determined by the Committee. Awards may provide that upon the grant or exercise thereof, the holder will receive cash, shares of PetVivo common stock, other securities or property, or any combination of these in a single payment, installments or on a deferred basis. The exercise price per share of any stock option and the grant price of any stock appreciation right may not be less than the fair market value of PetVivo common stock on the date of grant. The term of any award cannot be longer than ten years from the date of grant. Awards will be adjusted in the event of a stock dividend or other distribution, recapitalization, forward or reverse stock split, reorganization, merger or other business combination, or similar corporate transaction, in order to prevent dilution or enlargement of the benefits or potential benefits provided under the 2020 Plan. The 2020 Plan permits the following types of awards: stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards, other stock-based awards, and dividend equivalents. Units – Public Offering On August 13, 2021, the Company sold an aggregate of 2,500,000 4.50 5.625 43,556 196,000 4.50 The Company received gross proceeds of $ 11,253,850 8 1,473,067 4,891,531 4,889,252 In addition, pursuant to the Underwriting Agreement, the Company granted ThinkEquity a 45-day option to purchase up to 375,000 additional shares of common stock, and/or 375,000 additional warrants, to cover over-allotments in connection with the Offering, which ThinkEquity partially exercised to purchase 375,000 warrants on the closing date Pursuant to the Underwriting Agreement, we issued warrants (the “Underwriter’s Warrants”) to ThinkEquity to purchase 125,000 5 5.625 five years Common Stock For the nine months ended December 31, 2021, the Company issued 2,958,615 i) 80,522 230,000 2,658 2.89 ii) 4,500 4.44 40,000 iii) 36,915 42,188 1.33 iv) 79,767 90,500 1.40 v) 49,014 343,098 7.00 vi) 43,324 56,250 2.22 vii) 11,000 77,000 7.00 viii) 2,500,000 4.50 ix) 43,556 196,000 4.50 x) 40,038 48,786 1.40 xi) 1,594 1.27 2,031 xii) 42,000 210,000 xiii) 25,585 69,080 xiv) 500 2,000 xv) 300 For the nine months ended December 31, 2020, the Company issued 990,290 i) i) 30,000 32,453 ii) 20,000 34,709 20,000 34,709 17,291 52,000 iii) 12,500 22,000 10,000 17,600 2,500 4,400 iv) 15,257 12,053 25,000 15,257 1.20 v) 226,071 316,500 vi) 162,252 486,755 a. 33,619 b. 26,217 c. 22,993 d. 10,789 e. 10,711 f. 10,627 g. 10,550 h. 9,302 i. 9,300 j. 9,209 k. 8,935 vii) 25,003 25,383 25,382 25,000 382 1.02 viii) 263,568 368,995 1,729,005 ix) 32,347 42,188 1.33 x) 202,499 2.22 449,993 xi) 793 6,750 4.44 Time-Based Restricted Stock Units We have granted time-based restricted stock units to certain participants under the 2020 Plan that are stock-settled with common shares. Time-based restricted stock units granted under the 2020 Plan vest over three years. Stock-based compensation expense included in the Condensed Consolidated Statements of Operations for time-based restricted stock units was $ 251,885 359,992 1,762,000 1.8 Our time-based restricted stock unit activity for the nine months ended December 31, 2021 was as follows: SCHEDULE OF TIME BASED RESTRICTED STOCK UNITS Units Weighted Average Grant Date Fair Value Per Unit Aggregate Intrinsic Value (1) Balance at March 31, 2021 - - - Granted 549,565 $ 3.86 - Vested (300 ) 13.99 Balance at December 31, 2021 549,265 $ 3.85 $ 2,071,000 (1) The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of this period. Warrants During the nine months ended December 31, 2021, the Company issued warrants to purchase an aggregate of 3,043,556 ● warrants to purchase 2,500,000 4,805,528 5.625 ● warrants to purchase 43,556 196,000 83,724 5.625 ● warrants to purchase 500,000 5.625 These warrants’ values were arrived at by using the Black-Scholes valuation model with the following assumptions: i) an expected volatility of the Company’s shares on the date of the grants of approximately 315 ii) risk-free rate identical to the U.S. Treasury 5 0.82 During the nine months ended December 31, 2020, the Company issued warrants to purchase a total of 240,627 i) warrants issued for 10,000 17,291 4.00 3 ii) warrants issued for 38,837 57,717 1.40 1.60 1.52 iii) warrants issued with debt for 158,036 265,500 91,500 1.40 iv) warrants for 3,750 6,600 5 1.20 v) warrants for 30,000 96,000 5 1.40 These warrants’ values were arrived at by using the Black-Scholes valuation model with the following assumptions: i) an expected volatility of the Company’s shares on the date of the grants of between approximately 350 433 ii) risk-free rates identical to the U.S. Treasury 3 5 0.29 1.16 A summary of warrant activity for the year ending March 31, 2020 and nine-month period ending December 31, 2021 is as follows: SCHEDULE OF WARRANT ACTIVITY Number of Warrants Weighted- Average Exercise Price Warrants Exercisable Weighted- Average Exercisable Price Outstanding, March 31, 2020 1,234,295 $ 2.12 1,027,092 $ 2.13 Issued in conjunction with convertible debt 158,036 1.40 Sold for Cash 10,000 4.00 Issued and granted 72,596 1.52 Exercised for cash (205,946 ) (2.21 ) Cashless warrant exercises (142,313 ) (1.64 ) Expired (45,000 ) (3.78 ) Outstanding, March 31, 2021 1,081,668 2.02 881,982 2.00 Issued and granted 3,043,556 5.63 Exercised for cash (6,094 ) (6.90 ) Cashless warrant exercises (237,724 ) (1.58 ) Expired (15,922 ) (5.28 ) Cancelled (108,000 ) (1.80 ) Outstanding, December 31, 2021 3,757,484 $ 4.95 3,684,359 $ 5.01 At December 31, 2021, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: SCHEDULE OF RANGE OF WARRANT PRICES Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Number of Warrants Weighted- Average Exercise Price $ 1.20 2.00 418,237 $ 1.35 4.18 418,237 $ 1.35 2.01 4.00 207,938 2.48 2.58 134,813 2.62 4.01 6.67 3,131,309 5.60 4.51 3,131,309 5.60 Total 3,754,484 4.95 4.36 3,684,359 5.01 For the three months ended December 31, 2021 and 2020, the total stock-based compensation on all instruments was $ 272,717 124,490 432,483 889,597 62,000

SUBSEQUENT EVENT

SUBSEQUENT EVENT	9 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENT	NOTE 16 – SUBSEQUENT EVENT In October 2021, the Company entered into a new lease agreement of 2,376 2,673 2.5 In January 2022, the Company issued 17,500 10,000 7,500

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies)	9 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description	(A) Organization and Description The Company is in the business of commercializing its proprietary medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in Minneapolis, Minnesota.
Basis of Presentation	(B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. In October 2020, the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was effectuated on December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 250,000,000
Principles of Consolidation	(C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations, Gel-Del Technologies, Inc. and PetVivo, Inc. All intercompany accounts have been eliminated upon consolidation.
Use of Estimates	(D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangibles, estimate of fair value of share-based payments and derivative instruments and recorded debt discount and valuation of deferred tax assets.
Cash and Cash Equivalents	(E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had no
Concentration-Risk	(F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. As of December 31, 2021, the Company did have cash balances in excess of the federally insured limits. At March 31, 2021, the Company did not have any cash balances in excess of the federally insured limits.
Property & Equipment	(H) Property & Equipment Property and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after considering their respective estimated residual values) over the assets estimated useful life of ( 3 5 7
Patents and Trademarks	(I) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of a useful life of 60 months
Loss Per Share	(J) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 3,754,484 1.20 6.67 4.95 The Company has 1,124,803 1.20 15.53 1.99 The Company uses the guidance in Accounting Standards Codification 260 (“ASC 260”) to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be antidilutive. At December 31, 2020, the Company had $ 280,000 0 June 30, 2021 280,000 0 96,924 2.89 196,000
Revenue Recognition	(K) Revenue Recognition The Company derives revenue from the sale of pet care products to its veterinarian customers in the Unites States. For performance obligations related to the sale of our pet care products, control transfers to the customer at a point in time. Revenue is recognized upon shipment, which is when control of these products is transferred to our customers and in an amount that reflects the consideration the Company expects to receive for these products. Shipping costs charged to customers are not reported within revenue. The Company does not have any significant financing components as payment is received at or shortly after the point of sale.
Accounts Receivable	(L) Accounts Receivable Accounts receivable are recorded at management’s assessment of the expected consideration to be received, based on a detailed review of historical pricing adjustments and collections. Management relies on the results of the assessment, which includes payment history of the applicable customer as a primary source of information in estimating the collectability of our accounts receivable. We update our assessment on a quarterly basis, which to date has not resulted in any material adjustments to the valuation of our accounts receivable. We believe the assessment provides reasonable estimates of our accounts receivable valuation, and therefore believe that substantially all accounts receivable are fully collectible.
Research and Development	(M) Research and Development The Company expenses research and development costs as incurred.
Fair Value of Financial Instruments	(N) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, accrued expenses – related parties, notes payable and accrued interest, and notes payable and accrued interest - related party, notes payable – directors and others. The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2021 and March 31, 2021, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company had no
Stock-Based Compensation - Non-Employees	(O) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised.
Income Taxes	(P) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. As required by ASC Topic 450, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses.
Inventory	(Q) Inventory Inventories are recorded in accordance with ASC 330, Inventory, and are stated at the lower of cost or net realizable value. We account for inventories using the first in first out (FIFO) methodology.
Recent Accounting Pronouncements	(R) Recent Accounting Pronouncements The Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) - Accounting for Convertible Instruments and Contracts on an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exceptions. The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of the standard on the consolidated financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). The new ASU addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact this new guidance will have on its financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.
Reclassifications	(S) Reclassifications A certain account in the prior year financial statements has been reclassified for comparative purposes to conform with the presentation in the current year financial statements. Accrued expenses is reported separately from accounts payable in the balance sheet since the amounts are material. There was no effect on the change in net assets resulting from the reclassifications.

INVENTORY (Tables)

INVENTORY (Tables)	9 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORY	The inventory components are as follows: SCHEDULE OF INVENTORY December 31, 2021 March 31, 2021 Finished Goods $ 8,520 $ 36,973 Work in Process 31,424 - Raw Materials 65,021 8,773 Manufacturing Supplies - 1,322 Inventory, Gross 104,965 47,068 Reserve for Obsolete Inventory - (47,068 ) Total Net $ 104,965 $ -

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	The components of property and equipment were as follows: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, 2021 March 31, 2021 Leasehold improvements $ 214,354 $ 198,015 Production equipment 165,753 128,849 R&D equipment 25,184 25,184 Computer equipment and furniture 48,895 10,130 Total, at cost 454,086 362,178 Accumulated depreciation (184,960 ) (148,140 ) Total Net $ 269,226 $ 214,038

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS	The components of intangible assets, all of which are finite-lived, were as follows: SCHEDULE OF INTANGIBLE ASSETS December 31, 2021 March 31, 2021 Patents $ 3,860,057 $ 3,840,903 Trademarks 26,142 26,142 Total at cost 3,886,199 3,867,045 Accumulated Amortization (3,845,461 ) (3,839,113 ) Total net $ 40,738 $ 27,932

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended
	Dec. 31, 2021
Accrued Expenses
SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES	The components of accrued expenses were as follows: SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES December 31, 2021 March 31, 2021 Accrued payroll and related taxes $ 473,699 $ 221,774 Accrued lease termination expense 332,238 332,238 Total $ 805,937 $ 554,012

DERIVATIVE LIABILITY AND EXPE_2

DERIVATIVE LIABILITY AND EXPENSE (Tables)	9 Months Ended
	Dec. 31, 2021
Derivative Liability And Expense
SCHEDULE OF DERIVATIVE LIABILITY ASSUMPTIONS	The Company used the following assumptions for determining the fair value of the conversion feature in the RDCN referenced in Note 8 to these financial statements, under the binomial pricing model with Monte Carlo simulations at June 15, 2020, September 30, 2020 and October 26, 2020, the issuance, balance sheet, and conversion dates, respectively: SCHEDULE OF DERIVATIVE LIABILITY ASSUMPTIONS June 15, 2020 September 30, 2020 October 26,2020 Stock price on valuation date $ .42 $ .80 $ 6.56 Conversion price $ .28 $ .28 $ 1.12 Days to maturity 273 166 140 Weighted-average volatility* 367 % 327 197 % Risk-free rate .18 % .12 .11 %

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of December 31, 2021: SCHEDULE OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY 2022 $ 6,745 2023 27,167 2024 27,710 2025 28,265 2026 28,830 2027 19,475 Total 138,192 Less: amount representing interest (271 ) Total $ 137,921
SCHEDULE OF BASE RENT LEASE PAYMENTS	SCHEDULE OF BASE RENT LEASE PAYMENTS Present value of future base rent lease payments $ 137,921 Present value of future base rent lease payments – net $ 137,921
SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES	As of December 31, 2021, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES Operating lease right-of-use asset $ 137,921 Total operating lease assets 137,921 Operating lease current liability 27,011 Operating lease other liability 110,910 Total operating lease liabilities $ 137,921

COMMON STOCK AND WARRANTS (Tabl

COMMON STOCK AND WARRANTS (Tables)	9 Months Ended
	Dec. 31, 2021
Common Stock And Warrants
SCHEDULE OF TIME BASED RESTRICTED STOCK UNITS	Our time-based restricted stock unit activity for the nine months ended December 31, 2021 was as follows: SCHEDULE OF TIME BASED RESTRICTED STOCK UNITS Units Weighted Average Grant Date Fair Value Per Unit Aggregate Intrinsic Value (1) Balance at March 31, 2021 - - - Granted 549,565 $ 3.86 - Vested (300 ) 13.99 Balance at December 31, 2021 549,265 $ 3.85 $ 2,071,000 (1) The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of this period.
SCHEDULE OF WARRANT ACTIVITY	A summary of warrant activity for the year ending March 31, 2020 and nine-month period ending December 31, 2021 is as follows: SCHEDULE OF WARRANT ACTIVITY Number of Warrants Weighted- Average Exercise Price Warrants Exercisable Weighted- Average Exercisable Price Outstanding, March 31, 2020 1,234,295 $ 2.12 1,027,092 $ 2.13 Issued in conjunction with convertible debt 158,036 1.40 Sold for Cash 10,000 4.00 Issued and granted 72,596 1.52 Exercised for cash (205,946 ) (2.21 ) Cashless warrant exercises (142,313 ) (1.64 ) Expired (45,000 ) (3.78 ) Outstanding, March 31, 2021 1,081,668 2.02 881,982 2.00 Issued and granted 3,043,556 5.63 Exercised for cash (6,094 ) (6.90 ) Cashless warrant exercises (237,724 ) (1.58 ) Expired (15,922 ) (5.28 ) Cancelled (108,000 ) (1.80 ) Outstanding, December 31, 2021 3,757,484 $ 4.95 3,684,359 $ 5.01
SCHEDULE OF RANGE OF WARRANT PRICES	At December 31, 2021, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: SCHEDULE OF RANGE OF WARRANT PRICES Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Number of Warrants Weighted- Average Exercise Price $ 1.20 2.00 418,237 $ 1.35 4.18 418,237 $ 1.35 2.01 4.00 207,938 2.48 2.58 134,813 2.62 4.01 6.67 3,131,309 5.60 4.51 3,131,309 5.60 Total 3,754,484 4.95 4.36 3,684,359 5.01

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details Narrative) - USD ($)	Aug. 13, 2021	Apr. 30, 2021	Oct. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021	Dec. 29, 2020	Sep. 30, 2020	Jun. 30, 2020	Jun. 15, 2020
Reverse stock split, description			the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was effectuated on December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000; all share and per share data has been retroactively adjusted for this reverse split for all periods presented.
Common stock, shares authorized				250,000,000		250,000,000	225,000,000
Cash Equivalents, at Carrying Value						$ 0
Convertible notes interest		$ 2,658
Debt instrument maturity date				Apr. 30, 2020
Conversion of debt into common stock shares	43,556	80,522
Conversion price per share		$ 2.89						$ 0.28	$ 1.12	$ 0.28
Fair value, net asset (liability)				$ 0		$ 0
Income tax likelihood percentage				greater than 50 percent
Convertible Notes [Member]
Convertible notes outstanding					$ 280,000
Convertible notes interest					$ 0
Debt instrument maturity date					Jun. 30, 2021
Conversion of debt into common stock shares					96,924
Conversion price per share					$ 2.89
Share-settled debt obligation with a related party					$ 196,000
Warrant [Member]
Warrants outstanding				3,754,484	1,124,803
Warrant exercise price		$ 4.44
Weighted average, exercise price				$ 4.95	$ 1.99
Warrant [Member] | Minimum [Member]
Warrant exercise price				1.20	1.20
Warrant [Member] | Maximum [Member]
Warrant exercise price				$ 6.67	$ 15.53
Patents and Trademarks [Member]
Estimated useful life of intangible asset				60 months
Equipment [Member]
Estimated useful life of assets				3 years
Automobiles [Member]
Estimated useful life of assets				5 years
Furniture and Fixtures [Member]
Estimated useful life of assets				7 years

SCHEDULE OF INVENTORY (Details)

SCHEDULE OF INVENTORY (Details) - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Inventory Disclosure [Abstract]
Finished Goods	$ 8,520	$ 36,973
Work in Process	31,424
Raw Materials	65,021	8,773
Manufacturing Supplies		1,322
Inventory, Gross	104,965	47,068
Reserve for Obsolete Inventory		(47,068)
Total Net	$ 104,965

INVENTORY (Details Narrative)

INVENTORY (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventory, gross	$ 104,965	$ 47,068
Inventory reserves		47,068
Inventory written off	$ 47,068
Income recognized, change in reserve of obsolete inventory		$ 3,289

PREPAID EXPENSES AND DEFERRED_2

PREPAID EXPENSES AND DEFERRED OFFERING COSTS (Details Narrative) - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Prepaid expenses and other assets	$ 373,505	$ 123,575
Deferred offering costs		280,163
Insurance Costs [Member]
Prepaid expenses and other assets	245,000	9,000
Investor Relations Services [Member]
Prepaid expenses and other assets	82,000
Trade shows [Member]
Prepaid expenses and other assets	$ 36,000
Advertising and Marketing Services [Member]
Prepaid expenses and other assets		78,000
OTC Registration Fee [Member]
Prepaid expenses and other assets		$ 9,000

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Property, Plant and Equipment [Line Items]
Total, at cost	$ 454,086	$ 362,178
Accumulated depreciation	(184,960)	(148,140)
Total Net	269,226	214,038
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	214,354	198,015
Production Equipment [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	165,753	128,849
R&D Equipment [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	25,184	25,184
Furniture And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	$ 48,895	$ 10,130

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 13,123	$ 10,768	$ 36,820	$ 24,731

SCHEDULE OF INTANGIBLE ASSETS (

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 3,860,057	$ 3,840,903
Trademarks	26,142	26,142
Total at cost	3,886,199	3,867,045
Accumulated Amortization	(3,845,461)	(3,839,113)
Total net	$ 40,738	$ 27,932

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 2,286	$ 1,629	$ 6,348	$ 8,353

SCHEDULE OF COMPONENTS OF ACCRU

SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES (Details) - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Accrued Expenses
Accrued payroll and related taxes	$ 473,699	$ 221,774
Accrued lease termination expense	332,238	332,238
Total	$ 805,937	$ 554,012

ACCRUED EXPENSES (Details Narra

ACCRUED EXPENSES (Details Narrative) - USD ($)	Dec. 31, 2021	Mar. 31, 2021	Jan. 31, 2020
Accrued Expenses
Accrued expense	$ 332,000	$ 332,000	$ 7,500

RELATED PARTY NOTES PAYABLE (De

RELATED PARTY NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Mar. 31, 2021	Dec. 31, 2021
Notes payable and accrued interest	$ 44,554
Debt instrument maturity date		Apr. 30, 2020
Annual monthly payments		$ 3,100
Debt term		24 months
Four Directors [Member]
Notes payable and accrued interest	$ 20,000	$ 0
Debt interest rate	6.00%
Minimum [Member]
Proceeds from related party debt		$ 3,500,000

NOTES PAYABLE AND CONVERTIBLE_2

NOTES PAYABLE AND CONVERTIBLE NOTES (Details Narrative) - USD ($)	Aug. 13, 2021	Oct. 26, 2020	Oct. 26, 2020	Jun. 15, 2020	May 01, 2020	Jun. 30, 2021	Apr. 30, 2021	Oct. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021	Aug. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jan. 31, 2020
Short-term Debt [Line Items]
Notes payable																		$ 42,500
Debt instrument, interest rate																		6.00%
Convertible Notes payable									$ 35,100			$ 35,100		$ 39,528
Notes payable, current liabilities									6,456			6,456		39,528
Note payable. other liabilities									28,837			$ 28,837
Convertible notes maturity date												Apr. 30, 2020
Debt instrument, periodic monthly payment												$ 3,100
Accrued interest							$ 2,658
Debt conversion, shares issued	43,556						80,522
Conversion price per share				$ 0.28			$ 2.89				$ 0.28					$ 1.12
Number of warrants purchase	43,556
Discount on debt				$ 206,000
Stock price															$ 4.50
Debt conversion stock valued												232,658	$ 1,729,005
Gain on debt extinguishment										$ 366,903			$ 366,903
Warrant [Member]
Short-term Debt [Line Items]
Number of warrants purchase							4,500
Red Diamond Partners, LLC [Member]
Short-term Debt [Line Items]
Debt principal amount								$ 368,995
Accrued interest								$ 1,729,005
Conversion price per share		$ 1.40	$ 1.40
Unamortized debt discount											$ 215,686						$ 0
Debt principal and accrued interest		$ 368,995	$ 368,995
Shares of common stock issued		263,568						263,568
Gain on debt extinguishment		$ 366,903
Convertible Note Payable [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate														10.00%
Convertible Notes payable														$ 235,671
Debt principal amount														230,000
Accrued interest, current														5,671
Interest expenses														173,174
Convertible Notes Payable [Member] | Derivative [Member]
Short-term Debt [Line Items]
Discount on debt											206,000
Convertible Notes Payable [Member] | Investor [Member]
Short-term Debt [Line Items]
Discount on debt											2,500
Legal fees											2,500
Convertible Notes Payable [Member] | Think Warrants [Member]
Short-term Debt [Line Items]
Fair value of warrants											$ 31,500
Payment of convertible debt												61,500
Number of warrants issued											75,000
Convertible Notes Payable [Member] | Think Equity [Member]
Short-term Debt [Line Items]
Fair value of warrants									$ 52,399			$ 52,399
Convertible Notes Payable [Member] | Red Diamond Partners, LLC [Member]
Short-term Debt [Line Items]
Notes payable											$ 365,808
Debt principal amount				$ 352,941							352,941
Accrued interest											12,867
Shares issued, price per share				$ 0.28
Unamortized debt discount				$ 52,941							$ 52,941			0
Original issue discount percentage				15.00%
Number of warrants purchase											557,143
Fair value of warrants											$ 91,500
Reduction discounts on debt											0
Interest expenses											137,255
Payment of convertible debt											30,000
Owed amount														0
Convertible Notes Payable [Member] | Red Diamond Partners, LLC [Member] | Warrant [Member]
Short-term Debt [Line Items]
Discount on debt											$ 91,500
Paycheck Protection Program [Member]
Short-term Debt [Line Items]
Notes payable						$ 3,769								$ 39,020
Debt instrument, interest rate					1.00%
Debt principal amount					$ 38,665
Convertible notes maturity date					May 1, 2022
Forgiveness of debt						31,680
Debt instrument, periodic monthly payment						$ 738
Note Conversion Agreement [Member]
Short-term Debt [Line Items]
Debt principal amount		352,941	352,941
Accrued interest		$ 16,054	$ 16,054
Conversion price per share		$ 1.40	$ 1.40
Unamortized debt discount		$ 181,187	$ 181,187
Debt principal and accrued interest		$ 368,995	$ 368,995
Shares of common stock issued			263,568
Stock price		$ 6.56	$ 6.56
Derivative liability		$ 1,908,100	$ 1,908,100
Debt conversion stock valued			1,729,005
Gain on debt extinguishment			$ 366,903

SHARE-SETTLED DEBT OBLIGATION_2

SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY (Details Narrative) - USD ($)	Aug. 13, 2021	Sep. 02, 2020	Apr. 30, 2021	Dec. 31, 2021	Mar. 31, 2021	Oct. 15, 2020	Jan. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Accrued Interest			$ 2,658
Notes payable							$ 42,500
Debt interest rate							6.00%
Annual monthly payments				$ 3,100
Debt instrument maturity date				Apr. 30, 2020
Debt obligation converted	43,556		80,522
Common stock and warrants purchased	43,556
Warrants for purchase of common stock	43,556
Share-Settled Debt Obligations [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Notes payable					$ 196,000
Promissory Note [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Debt principal amount				$ 0	196,000
Related To Amendment Promissory Note [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Debt principal amount				$ 0	$ 44,554
David B Masters [Member] | Amended Promissory Note [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Debt principal amount		$ 59,642
Accrued Interest		6,058
Notes payable		$ 65,700
Debt interest rate		8.00%
Debt default interest rate		20.00%
Conditions of promissory notes, description		The Amendment to Promissory Note requires monthly payments of $3,100 and a maturity date of June 30, 2022, provided however that if the Company shall achieve $1,500,000 in equity sales or achieve gross product sales of $1,500,000, the Company must pay the outstanding balance at that time
Annual monthly payments		$ 3,100
Debt instrument maturity date		Jun. 30, 2022
David B Masters [Member] | Promissory Note [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Debt principal amount		$ 195,000				$ 192,500
Accrued Interest						658
Notes payable						193,158
Debt interest rate		3.00%
Conditions of promissory notes, description		David Masters’ release of any claim to the $195,000 in past accrued salary he was owed, it accrues interest at a rate of 3% per annum, has a maturity date of August 31, 2022, and required payments of $4,000 per month beginning when the Company’s sale of products reach $3,500,000. The reclassification of the $195,000 was treated as a debt modification
Annual monthly payments		$ 4,000
Debt instrument maturity date		Aug. 31, 2022
Debt modification		$ 195,000
David B Masters [Member] | Promissory Note [Member] | Conversion Agreement [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Debt principal amount						192,500
Accrued Interest						658
Notes payable						196,000
Unamortized discount on debt						3,500
Conversion fee						$ 3,500

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITY ASSUMPTIONS (Details)	Oct. 26, 2020$ / shares	Sep. 30, 2020$ / shares	Jun. 15, 2020$ / shares	Apr. 30, 2021$ / shares	Jun. 30, 2020$ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price on valuation date	$ 6.56	$ 0.80	$ 0.42
Conversion price		$ 0.28	$ 0.28	$ 2.89	$ 1.12
Days to maturity	140 days	166 days	273 days
Measurement Input, Option Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input, percentage	197	327	367
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input, percentage	0.11	0.12	0.18

DERIVATIVE LIABILITY AND EXPE_3

DERIVATIVE LIABILITY AND EXPENSE (Details Narrative) - USD ($)	Oct. 26, 2020	Jun. 15, 2020	Oct. 31, 2020	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Apr. 30, 2021	Jun. 30, 2020
Corresponding offset to derivative liability		$ 526,800
Discount on debt		206,000
Convertible note embedded derivative liability		0
Derivative expense		320,800		$ 937,500		$ 970,600		$ 1,702,100
Recognition of derivative liability		$ 526,800		$ 389,300
Conversion price per share		$ 0.28		$ 0.28					$ 2.89	$ 1.12
Gain on debt extinguishment						366,903		366,903
Derivative Liability						$ 0		$ 0
Red Diamond Partners, LLC [Member]
Shares of common stock issued	263,568		263,568
Conversion price per share	$ 1.40
Gain on debt extinguishment	$ 366,903

ACCRUED EXPENSES _ RELATED PA_2

ACCRUED EXPENSES – RELATED PARTY (Details Narrative) - USD ($)	1 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Accounts payable	$ 263,267	$ 408,873
Accrued salaries and payroll taxes payable	473,699	221,774
Proceeds from Issuance Initial Public Offering	$ 0
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued expenses, related party		36,808
Accounts payable		28,965
Accrued salaries and payroll taxes payable		$ 7,843

RETIREMENT PLAN (Details Narrat

RETIREMENT PLAN (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2021
Retirement Benefits [Abstract]
Discretionary contributions	$ 2,350	$ 2,350

SCHEDULE OF ANNUAL UNDISCOUNTED

SCHEDULE OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY (Details)	Dec. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 6,745
2023	27,167
2024	27,710
2025	28,265
2026	28,830
2027	19,475
Total	138,192
Less: amount representing interest	(271)
Total	$ 137,921

SCHEDULE OF BASE RENT LEASE PAY

SCHEDULE OF BASE RENT LEASE PAYMENTS (Details)	Dec. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Present value of future base rent lease payments	$ 137,921
Operating Lease, Liability	$ 137,921

SCHEDULE OF LEASE CURRENT AND N

SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES (Details) - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use asset	$ 137,921
Total operating lease assets	137,921	$ 157,760
Operating lease current liability	27,011	26,582
Operating lease other liability	110,910	$ 131,178
Operating lease liability	$ 137,921

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)	1 Months Ended		3 Months Ended		9 Months Ended
	Oct. 31, 2021USD ($)ft²	May 31, 2017ft²	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Mar. 31, 2021USD ($)	Jan. 31, 2020USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land | ft²	2,376	3,577
Annual increase in base rent, percentage	0.025	0.02
Lease term description		In January 2020, the Company entered into a lease amendment whereby agreed to extend the lease term through November of 2026
Notes Payable								$ 42,500
Accrued expenses			$ 332,000		$ 332,000		$ 332,000	$ 7,500
Base rent	$ 2,673		2,205		2,205		2,205
Lease rent expenses			$ 16,549	$ 13,343	$ 50,952	$ 40,479
Operating lease treasury rate			0.12%		0.12%
Operating lease right-of-use			$ 137,921		$ 137,921		$ 157,760
Weighted average remaining lease term			6 years		6 years
Weighted average discount rate			0.12%		0.12%
Extended Lease Term To 2026 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease right-of-use			$ 189,600		$ 189,600

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	1 Months Ended
	Aug. 31, 2021	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from sale of stock	$ 9,781,000
Number of stock, sold during period	2,500,000
Sale of stock, price per share	$ 4.50
Working capital		$ 6,928,954

SCHEDULE OF TIME BASED RESTRICT

SCHEDULE OF TIME BASED RESTRICTED STOCK UNITS (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time based RSU's, Balance
Time based RSU's, Weighted Average Grant Date Fair Value Per Unit | $ / shares
Aggregate Intrinsic Value, RSU's, Balance		[1]
Time based RSU's Granted	549,565
Time based RSU's, Weighted Average Grant Date Fair Value Per Unit, Granted | $ / shares	$ 3.86
Aggregate Intrinsic Value, RSU's, Granted | $ / shares		[1]
Time based RSU's Vested	(300)
Time based RSU's, Weighted Average Vested Date Fair Value Per Unit, Vested | $ / shares	$ 13.99
Time based RSU's, Balance	549,265
Time based RSU's, Weighted Average Grant Date Fair Value Per Unit | $ / shares	$ 3.85
Aggregate Intrinsic Value, RSU's, Balance	2,071,000	[1]
[1]	The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of this period.

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member] - $ / shares	9 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021
Number of Warrants, Outstanding, Balance	1,081,668	1,234,295	1,234,295
Weighted-Average Exercise Price, Outstanding, Balance	$ 2.02	$ 2.12	$ 2.12
Warrants Exercisable, Outstanding, Balance	881,982	1,027,092	1,027,092
Weighted-Average Exercisable Price, Outstanding, Balance	$ 2	$ 2.13	$ 2.13
Number of Warrants, Issued in conjunction with convertible debt			158,036
Weighted-Average Exercise Price, Issued in conjunction with convertible debt			$ 1.40
Number of Warrants, Sold			10,000
Weighted-Average Exercise Price, Sold for cash			$ 4
Number of Warrants, Granted	3,043,556	240,627	72,596
Weighted-Average Exercise Price, Issued and granted	$ 5.63		$ 1.52
Number of Warrants, Exercised for cash	(6,094)		(205,946)
Weighted-Average Exercise Price, Exercised for cash	$ (6.90)		$ (2.21)
Number of Warrants, Cashless warrant exercises	(237,724)		(142,313)
Weighted-Average Exercise Price, Cashless warrant exercises	$ (1.58)		$ (1.64)
Number of Warrants, Expired	(15,922)		(45,000)
Weighted-Average Exercise Price, Expired	$ (5.28)		$ (3.78)
Number of Warrants, Cancelled	(108,000)
Weighted-Average Exercise Price, Cancelled	$ (1.80)
Number of Warrants, Outstanding, Balance	3,757,484		1,081,668
Weighted-Average Exercise Price, Outstanding, Balance	$ 4.95		$ 2.02
Number of Warrants, Exercisable	3,684,359		881,982
Weighted-Average Exercise Price, Exercisable	$ 5.01		$ 2

SCHEDULE OF RANGE OF WARRANT PR

SCHEDULE OF RANGE OF WARRANT PRICES (Details) - Warrant [Member] - $ / shares	9 Months Ended
	Dec. 31, 2021	Apr. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Warrant exercise price		$ 4.44
Number of Warrants, Outstanding	3,754,484
Weighted-Average Exercise Price, outstanding	$ 4.95		$ 2.02		$ 2.12
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 4 months 9 days
Number of Warrants, Exercisable	3,684,359		881,982		1,027,092
Weighted-Average Exercise Price, Exercisable	$ 5.01		$ 2		$ 2.13
Range One [Member]
Number of Warrants, Outstanding	418,237
Weighted-Average Exercise Price, outstanding	$ 1.35
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 2 months 4 days
Number of Warrants, Exercisable	418,237
Weighted-Average Exercise Price, Exercisable	$ 1.35
Range Two [Member]
Number of Warrants, Outstanding	207,938
Weighted-Average Exercise Price, outstanding	$ 2.48
Weighted-Average Remaining Contractual Life (Years), Outstanding	2 years 6 months 29 days
Number of Warrants, Exercisable	134,813
Weighted-Average Exercise Price, Exercisable	$ 2.62
Range Three [Member]
Number of Warrants, Outstanding	3,131,309
Weighted-Average Exercise Price, outstanding	$ 5.60
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 6 months 3 days
Number of Warrants, Exercisable	3,131,309
Weighted-Average Exercise Price, Exercisable	$ 5.60
Minimum [Member]
Warrant exercise price	1.20			$ 1.20
Minimum [Member] | Range One [Member]
Warrant exercise price	1.20
Minimum [Member] | Range Two [Member]
Warrant exercise price	2.01
Minimum [Member] | Range Three [Member]
Warrant exercise price	4.01
Maximum [Member]
Warrant exercise price	6.67			$ 15.53
Maximum [Member] | Range One [Member]
Warrant exercise price	2
Maximum [Member] | Range Two [Member]
Warrant exercise price	4
Maximum [Member] | Range Three [Member]
Warrant exercise price	$ 6.67

COMMON STOCK AND WARRANTS (Deta

COMMON STOCK AND WARRANTS (Details Narrative)	Aug. 13, 2021USD ($)$ / sharesshares	Oct. 26, 2020$ / sharesshares	Sep. 14, 2020USD ($)shares	Aug. 14, 2020USD ($)$ / sharesshares	Jul. 24, 2020USD ($)$ / sharesshares	Jul. 10, 2020shares	Jul. 01, 2020USD ($)$ / sharesshares	Dec. 31, 2021USD ($)$ / sharesshares	Oct. 31, 2021USD ($)shares	Sep. 30, 2021USD ($)$ / sharesshares	Aug. 31, 2021USD ($)$ / sharesshares	Jul. 31, 2021USD ($)$ / sharesshares	Jun. 30, 2021$ / sharesshares	May 31, 2021$ / sharesshares	Apr. 30, 2021USD ($)$ / sharesshares	Oct. 31, 2020USD ($)$ / sharesshares	Jun. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2021USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / shares	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / shares	Jun. 30, 2020USD ($)$ / shares	Mar. 31, 2020USD ($)shares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2021shares	Sep. 01, 2020USD ($)$ / sharesshares	Jun. 15, 2020$ / shares
Number of stock, sold during period											2,500,000
Sale of stock price per share | $ / shares											$ 4.50
Conversion of debt into common stock shares	43,556														80,522
Conversion of notes | $															$ 230,000
Conversion price per share | $ / shares															$ 2.89			$ 0.28					$ 0.28	$ 1.12						$ 0.28
Proceeds from Issuance Initial Public Offering | $								$ 0
Number of warrants purchase	43,556
Accrued interest | $															$ 2,658
Common stock sold | $																				$ 4,968,531	$ 343,098		$ 316,500
Stock issued for services | $																			$ 71,080			$ 72,000
Stock-based Compensation | $																			272,717	$ 104,092	$ 55,674	52,490	$ 653,863	$ 183,244
Proceeds from sale of stock | $											$ 9,781,000
Restricted Stock or Unit Expense | $																			251,885							$ 359,992
Unrecognized pre-tax compensation expenses | $								$ 1,762,000											1,762,000							$ 1,762,000
RSU recognized weighted average period																										1 year 9 months 18 days
Stock-based Compensation | $																			$ 272,717			$ 124,490				$ 432,483	$ 889,597
Expense related to warrants issued and outstanding | $																										$ 62,000
Measurement Input, Price Volatility [Member]
Warrant measurement inputs								315											315							315
Measurement Input, Price Volatility [Member] | Minimum [Member]
Warrant measurement inputs																						350					350
Measurement Input, Price Volatility [Member] | Maximum [Member]
Warrant measurement inputs																						433					433
Measurement Input, Expected Term [Member]
Warrants exercise term								5 years											5 years							5 years
Measurement Input, Expected Term [Member] | Minimum [Member]
Warrants exercise term																						3 years					3 years
Measurement Input, Expected Term [Member] | Maximum [Member]
Warrants exercise term																						5 years					5 years
Measurement Input, Risk Free Interest Rate [Member]
Warrant measurement inputs								0.82											0.82							0.82
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Warrant measurement inputs																						0.29					0.29
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Warrant measurement inputs																						1.16					1.16
Red Diamond Partners, LLC [Member]
Conversion price per share | $ / shares		$ 1.40
Accrued interest | $																$ 1,729,005
Debt principal amount | $																$ 368,995
Shares of common stock issued		263,568														263,568
One Share of Common Stock and 1/2 Warrant Share [Member]
Number of stock, sold during period																									20,000
Proceeds from Issuance of Warrants | $																									$ 34,709
Warrant transaction cost | $																									17,291
Proceeds from sale of stock | $																									$ 52,000
Restricted Stock Units (RSUs) [Member]
Common stock sold, shares								300
Common Stock [Member]
Common stock sold, shares																										2,958,615	990,290
Warrant [Member]
Warrant exercise price | $ / shares															$ 4.44
Number of warrants purchase															4,500
Proceeds from warrant exercise | $															$ 40,000
Number of Warrants, Granted																										3,043,556	240,627	72,596
Warrant [Member] | Minimum [Member]
Warrant exercise price | $ / shares								$ 1.20											$ 1.20			$ 1.20				$ 1.20	$ 1.20
Warrant [Member] | Maximum [Member]
Warrant exercise price | $ / shares								6.67											6.67			15.53				6.67	$ 15.53
Warrant [Member] | Think Equity [Member]
Warrant exercise price | $ / shares								$ 5.625											$ 5.625							$ 5.625
Common stock sold, shares																										500,000
IPO [Member]
Warrant exercise price | $ / shares	$ 4.50
Conversion of debt into common stock shares											43,556
Conversion of notes | $											$ 196,000
Conversion price per share | $ / shares											$ 4.50
Proceeds from Issuance Initial Public Offering | $	$ 11,253,850
Underwriting Expense Ratio	8.00%
Equity public offerings | $	$ 1,473,067
Proceeds from issuance of common shares | $	4,891,531
Proceeds from Issuance of Warrants | $	$ 4,889,252
Common stock sold, shares	2,500,000
IPO [Member] | Warrant [Member]
Number of warrants purchase								3,043,556											3,043,556							3,043,556
John Lai's [Member]
Warrant exercise price | $ / shares														$ 1.33
Number of warrants purchase														42,188
Common stock sold, shares														36,915
Stock-based Compensation, shares			33,619
Warrant Holders [Member]
Warrant exercise price | $ / shares										$ 1.27	$ 1.40		$ 2.22	$ 1.40			$ 2.22			$ 1.27	$ 2.22
Number of warrants purchase											48,786		56,250	90,500			56,250				56,250
Common stock sold, shares										1,594	40,038		43,324	79,767
Proceeds from warrant exercise | $										$ 2,031
Accredited Investors [Member]
Warrant exercise price | $ / shares												$ 7	$ 7				$ 7				$ 7
Common stock sold, shares												11,000					49,014
Common stock sold | $												$ 77,000					$ 343,098
Service Provider [Member]
Stock issued for services, shares								500		42,000
Stock issued for services | $								$ 2,000		$ 210,000
Stock-based Compensation, shares																											30,000
Stock-based Compensation | $																											$ 32,453
Board of Director [Member]
Common stock sold, shares									25,585
Common stock sold | $									$ 69,080
Two Service Provider [Member]
Stock issued for services, shares							12,500
Stock issued for services | $							$ 22,000
Marketing and Investor Relations Service Provider [Member]
Stock issued for services, shares							10,000
Stock issued for services | $							$ 17,600
Legal Service Provider [Member]
Stock issued for services, shares							2,500
Stock issued for services | $							$ 4,400
One Warrant Holder [Member]
Warrant exercise price | $ / shares					$ 1.20
Common stock sold, shares					15,257
Common stock sold | $					$ 12,053
Warrants converted on cashless basis					25,000
Four Accredited Investors [Member]
Common stock sold, shares																		226,071
Common stock sold | $																		$ 316,500
Directors and Officers [Member]
Stock-based Compensation, shares			162,252
Stock-based Compensation | $			$ 486,755
John Carruth [Member]
Stock-based Compensation, shares			26,217
John Dolan [Member]
Stock-based Compensation, shares			22,993
Gregory Cash [Member]
Stock-based Compensation, shares			10,789
David Deming [Member]
Stock-based Compensation, shares			10,711
Robert Rudelius [Member]
Stock-based Compensation, shares			10,627
Randy Meyer [Member]
Stock-based Compensation, shares			10,550
Jim Martin [Member]
Stock-based Compensation, shares			9,302
Scott Johnson [Member]
Stock-based Compensation, shares			9,300
Joseph Jasper [Member]
Stock-based Compensation, shares			9,209
David Masters [Member]
Stock-based Compensation, shares			8,935
Three Directors [Member]
Conversion of notes | $				$ 25,383
Conversion price per share | $ / shares				$ 1.02
Accrued interest | $				$ 382
Number of shares issued for conversion				25,003
Outstanding balance | $				$ 25,382
Debt principal amount | $				$ 25,000
John Lais [Member]
Conversion price per share | $ / shares																$ 1.33
Common stock sold, shares																42,188
Shares of common stock issued																32,347
Twenty Accredited Investors [Member]
Conversion price per share | $ / shares																						$ 2.22					$ 2.22
Proceeds from warrant exercise | $																						$ 449,993
Shares of common stock issued																						202,499
Investors [Member] | Warrant [Member]
Warrant exercise price | $ / shares								$ 5.625											$ 5.625							$ 5.625
Common stock sold | $																										$ 4,805,528
Warrants to purchase common stock								2,500,000											2,500,000							2,500,000
Director [Member] | Warrant [Member]
Warrant exercise price | $ / shares								$ 5.625											$ 5.625							$ 5.625
Conversion of notes | $																										$ 196,000
Warrants to purchase common stock								43,556											43,556							43,556
Conversion of Stock, Amount Issued | $																										$ 83,724
One Investor [Member] | Warrant [Member]
Warrant exercise price | $ / shares																						$ 4					$ 4
Number of warrants purchase																						10,000					10,000
Warrants exercise term																						3 years					3 years
Warrant to purchase of common stock, value | $																						$ 17,291					$ 17,291
Directors Officers and Consultants [Member] | Warrant [Member]
Warrant exercise price | $ / shares																						$ 1.52					$ 1.52
Number of warrants purchase																						38,837					38,837
Warrant to purchase of common stock, value | $							$ 6,600															$ 57,717					$ 57,717
Directors Officers and Consultants [Member] | Warrant [Member] | Minimum [Member]
Warrant exercise price | $ / shares																						$ 1.40					$ 1.40
Directors Officers and Consultants [Member] | Warrant [Member] | Maximum [Member]
Warrant exercise price | $ / shares																						1.60					1.60
Investor and Broker [Member] | Warrant [Member]
Warrant exercise price | $ / shares																						$ 1.40					$ 1.40
Number of warrants purchase																						158,036					158,036
Warrant to purchase of common stock, value | $																						$ 265,500					$ 265,500
Value of warrant vested | $																											$ 91,500
Two Directors [Member] | Warrant [Member]
Warrant exercise price | $ / shares							$ 1.20
Number of warrants purchase							3,750
Warrants exercise term							5 years
Director Consulting Serives [Member] | Warrant [Member]
Warrant exercise price | $ / shares																													$ 1.40
Number of warrants purchase																													30,000
Warrants exercise term																													5 years
Warrant to purchase of common stock, value | $																													$ 96,000
2020 Equity Incentive Plan [Member]
Number of shares of our common stock authorized						1,000,000
Expiration date						Jul. 10, 2030
Number of shares available to grant								450,435											450,435							450,435
Common stock available and reserved to be issued						1,000,000
2020 Equity Incentive Plan [Member] | Non employee Director [Member]
Maximum aggregate number of shares of common stock granted						25,000
Underwriting Agreement [Member]
Number of stock, sold during period	2,500,000
Sale of stock price per share | $ / shares	$ 4.50
Warrant exercise price | $ / shares	$ 5.625							$ 5.625											$ 5.625							$ 5.625
Conversion of debt into common stock shares	43,556
Conversion of notes | $	$ 196,000
Conversion price per share | $ / shares	$ 4.50
Underwriting agreement of shares, description																										In addition, pursuant to the Underwriting Agreement, the Company granted ThinkEquity a 45-day option to purchase up to 375,000 additional shares of common stock, and/or 375,000 additional warrants, to cover over-allotments in connection with the Offering, which ThinkEquity partially exercised to purchase 375,000 warrants on the closing date
Number of warrants purchase	125,000
Sale of stock in puplic offering	0.05
Warrants exercise term	5 years
Warrant Holders [Member]
Conversion price per share | $ / shares																$ 4.44
Common stock sold, shares																6,750
Shares of common stock issued																793

SUBSEQUENT EVENT (Details Narra

SUBSEQUENT EVENT (Details Narrative)	1 Months Ended
	Jan. 31, 2022shares	Dec. 31, 2021USD ($)shares	Oct. 31, 2021USD ($)ft²	May 31, 2017ft²	Mar. 31, 2021USD ($)
Subsequent Event [Line Items]
Area of land | ft²			2,376	3,577
Base rent | $		$ 2,205	$ 2,673		$ 2,205
Annual increase in base rent, percentage			0.025	0.02
Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Vested restricted stock		300
Subsequent Event [Member]
Subsequent Event [Line Items]
Vested restricted stock	17,500
Subsequent Event [Member] | Consultant [Member]
Subsequent Event [Line Items]
Shares issued to consultant for investor relations services	7,500
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Vested restricted stock	10,000